4-(2,6,6-Trimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepin-7-ylboronic acid → N-ethyl-6-[4-(2,6,6-trimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-imidazo[4,5-b]pyridin-2-amine

참여 물질

반응 단계

Prepared according to the method of example 5 by using 6-bromo-N-ethyl-1-[(methyloxy)methyl]-1H-imidazo[4,5-b]pyridin-2-amine (reagent preparation 36) and [4-(2,6,6-trimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]boronic acid (reagent preparation 23) in step 1 followed by MOM deprotection. 1H NMR (400 MHz, methanol-d4): 8.15 (d, 1H), 7.64 (d, 1H), 7.55 (d, 1H), 7.43 (dd, 1H), 7.06 (d, 1H), 4.71 (s, 2H), 4.31 (m, 2H), 3.99 (m, 2H), 3.46 (q, 2H), 2.75 (t, 2H), 2.47 (s, 2H), 2.41 (s, 3H), 1.66 (t, 2H), 1.30 (t, 3H), 0.91 (s, 6H); MS (EI) for C27H30N6O: 455 (MH+).

출처 및 근거